Skip to content


Once-Daily PREZCOBIX® Helps Reduce Pill Burden

Coformulated in a fixed-dose combination1

Pill image 01


The recommended dose of PREZCOBIX® is one tablet taken once daily with food as part of combination ARV therapy for HIV-1–infected adults with no DRV RAMs*1

PREZCOBIX® combined with DESCOVY® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) can be used in HIV-1–infected adults who have a CrCl ≥30 mL/min†2

  • This recommendation is based on drug-drug interaction studies‡2,3
  • No clinically significant drug interactions have been observed or expected2,3

* DRV RAMs=darunavir resistance-associated mutations: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V.

When PREZCOBIX® is used with TDF/FTC, HIV-1–infected adults must have a CrCl ≥70 mL/min.1

This DHHS recommendation is based on data from comparative trials demonstrating that TAF-containing regimens are as effective in achieving or maintaining virologic suppression as TDF-containing regimens, but with more favorable effects on markers of renal and bone health.2



Drugs that are contraindicated
Alpha 1-adrenoreceptor antagonist: alfuzosin
Anticonvulsants: carbamazepine, phenobarbital, phenytoin
Anti-gout: colchicine in patients with renal or hepatic impairment
Antimycobacterial: rifampin
Antipsychotics: lurasidone, pimozide
Cardiac Disorders: dronedarone, ivabradine, ranolazine
Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
Gastrointestinal motility agent: cisapride
Hepatitis C direct-acting antivirals: elbasvir/grazoprevir
Herbal product: St. John's Wort (Hypericum perforatum)
Lipid modifying agents: lomitapide, lovastatin, simvastatin
Opioid Antagonist: naloxegol
PDE-5 inhibitor: sildenafil for treatment of pulmonary arterial hypertension
Sedatives/hypnotics: midazolam (oral), triazolam
Coadministration not recommended
Anticoagulant: rivaroxaban
Anticonvulsants: oxcarbazepine, eslicarbazepine
Antifungal: voriconazole
Antimycobacterial: rifapentine
Systemic/Inhaled/Nasal/Ophthalmic Corticosteroids: betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, triamcinolone
Hepatitis C direct-acting antivirals: glecaprevir/pibrentasvir, simeprevir
Immunosuppressant/neoplastic: everolimus
Inhaled β-agonist: salmeterol
NNRTIs: efavirenz, etravirine, nevirapine
PDE-5 inhibitor: avanafil
PK-boosted ARVs: other HIV PIs or elvitegravir
Platelet aggregation inhibitor: ticagrelor

No dose adjustment required*1

Acid modifying medications: antacids, H2-receptor antagonists, proton pump inhibitors
INSTIs: dolutegravir, raltegravir
NNRTI: rilpivirine
NRTIs: all NRTIs except for didanosine

* No clinically relevant drug-drug interaction is expected when PREZCOBIX® is coadministered.

ARV=antiretroviral; CrCl=creatinine clearance; DHHS=Department of Health and Human Services; INSTI=integrase strand transfer inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; PDE-5=phosphodiesterase type 5; PI=protease inhibitor; PK=pharmacokinetic; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.

References: 1. PREZCOBIX® [Prescribing Information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP. 2. Department of Health & Human Services. Guidelines for the use of antiretroviral agents in HIV-1–infected adults and adolescents. Published October 17, 2016. Accessed October 17, 2017. 3. Data on file. Janssen Therapeutics, Division of Janssen Products, LP.